astronomy

Julianna Lisziewicz

Julianna Lisziewicz is a astronomy topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Julianna Lisziewicz rather than just read about it. In short: Julianna Lisziewicz is a Hungarian-German immunologist, molecular biologist, and biotechnology entrepreneur known for pioneering work in gene therapy, antisense therapy, and personalized immunotherapy for HIV/AIDS and cancer. Early life and education Lisziewicz earned an MSc in Chemistry and Biology from the Budapest University of Technology and a PhD in Molecular Biology from the Max Planck Institute.

Key takeaways

Julianna Lisziewicz belongs to astronomy; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Julianna Lisziewicz to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Julianna Lisziewicz from memory before moving on to harder problems.

Reference excerpt

Julianna Lisziewicz is a Hungarian-German immunologist, molecular biologist, and biotechnology entrepreneur known for pioneering work in gene therapy, antisense therapy, and personalized immunotherapy for HIV/AIDS and cancer.

Early life and education Lisziewicz earned an MSc in Chemistry and Biology from the Budapest University of Technology and a PhD in Molecular Biology from the Max Planck Institute. She completed post-doctoral research at the Max Planck Institute for Experimental Medicine in Germany.

Career From 1989 to 1995 Lisziewicz worked at the U.S. National Institutes of Health (NIH), where she led the Antiviral Unit at the National Cancer Institute. During this period she co-invented one of the earliest gene-therapy approaches for HIV, developing the poly-TAR antisense construct—a genetic cassette that blocked transcription of the viral genome by targeting the trans-activation response (TAR) element. This invention, filed and patented by the NIH with Lisziewicz as inventor, was among the first demonstrations that antisense and gene therapy could inhibit HIV replication in human cells. In 1995 she founded the nonprofit Research Institute for Genetic and Human Therapy (RIGHT), integrating molecular virology and translational immunology. She subsequently founded Genetic Immunity Inc., which developed the DermaVir Patch, a dendritic-cell-targeted DNA vaccine for HIV. Her work gained international attention after publication of the New England Journal of Medicine report “Control of HIV despite the discontinuation of antiretroviral therapy” (N Engl J Med. 1999; 340(21):1683–1684), describing the Berlin Patient, the first documented case showing that the human immune system can control a chronic viral disease without continuous antiretroviral therapy. This discovery reshaped understanding of immune control and became a foundation for therapeutic vaccination strategies. Lisziewicz led the DermaVir program from discovery through full translational development, including preclinical studies in mice, pigs, rabbits, and monkeys, and Phase I and II clinical trials in HIV-infected patients. Her work demonstrated the feasibility, safety and preliminary efficacy of dendritic-cell-targeted nanomedicine as a therapeutic vaccination platform. She has extensive regulatory experience with both the U.S. FDA and the European Medicines Agency (EMA), enabling her to bring novel immunotherapeutic discoveries from concept to clinical testing. Lisziewicz later founded eMMUNITY LLC, a U.S. biotechnology company that evolved into TREOS Bio Ltd. (UK), which applies machine-learning-based epitope modeling to design PolyPEPI™ vaccines for colorectal and other solid cancers. She is currently the Founder and CEO of VERDI Solutions GmbH (Vienna, Austria), creator of the VERDI System (Vaccine Epitopes Ranked by Digital Intelligence)—a computational cloud platform integrating patient-specific HLA genotypes and tumor-antigen data to design personalized peptide vaccines.

Research and scientific contributions Lisziewicz’s research spans genetics, immune-system engineering, translational oncology, and vaccine development. At NIH she contributed to early antisense-oligonucleotide and gene-therapy studies for viral inhibition. At Genetic Immunity she led the full translational development of DermaVir, taking the therapeutic vaccine from bench discovery through preclinical animal models and into human clinical trials. The success of this program established a regulatory and translational framework later applied to cancer immunotherapy. In 2025 she and collaborators published a case report in Exploration of Immunology describing personalized VERDI peptide vaccines for metastatic signet ring cell carcinoma (SRCC), which elicited robust T-cell responses and prolonged survival. Her work established a continuous innovation pathway from immune control of chronic infection to personalized immunotherapy for cancer, highlighting her unique expertise in advancing laboratory discoveries into patient-ready treatments.

Translational impact Lisziewicz is recognized for her ability to translate groundbreaking laboratory discoveries into clinical applications. She has guided multiple therapeutic platforms—ranging from gene therapy and nanomedicine to personalized peptide vaccines—through the entire translational pathway, encompassing discovery, preclinical validation, clinical manufacturing, regulatory engagement, and human trials. Her leadership across RIGHT, Genetic Immunity, TREOS Bio, and VERDI Solutions demonstrates an integrated approach to advancing immunotherapies from concept to patient benefit.

Philosophy and vision Lisziewicz has argued that conventional cancer care is “unsustainably expensive and fails to deliver the optimal chance for recovery”. Her mission is to personalize cancer therapy by optimizing the standard of care in combination with patient-specific immunotherapy, improving both efficacy and affordability.

Selected patents US 5,837,533 — Gene therapy for HIV infection using poly-TAR antisense sequences (Assignee: U.S. Dept. of Health and Human Services; Inventor: Julianna Lisziewicz et al.). US 7,196,186 B2 — DNA composition and uses thereof (Assignee: Genetic Immunity Inc.). WO 2018/158455 A1 — Peptide vaccines (Assignee: TREOS Bio Ltd.). IL 320668 A — Personalized peptide vaccines and methods for treating cancer (Assignee: VERDI Solutions GmbH). These patents trace Lisziewicz’s innovations from early gene therapy at the NIH through personalized peptide-vaccine design at VERDI Solutions.

Companies founded Research Institute for Genetic and Human Therapy (RIGHT) – nonprofit research organization (1995) Genetic Immunity Inc. – developer of the DermaVir therapeutic vaccine (early 2000s) eMMUNITY LLC → TREOS Bio Ltd. – developer of the PolyPEPI™ precision-vaccine platform (2010s) VERDI Solutions GmbH – developer of the VERDI personalized cancer-vaccine platform (2020s)

Academic and professional appointments Founder & CEO, VERDI Solutions GmbH Founder, eMMUNITY LLC (later TREOS Bio Ltd.) Founder, Genetic Immunity Inc. Founder, Research Institute for Genetic and Human Therapy (RIGHT) Adjunct Professor of Microbiology, Georgetown University (Washington, D.C.) Marie Curie Chair Professor, Semmelweis University (Budapest) Former Senior Investigator, National Cancer Institute (NIH)

… excerpt ends here. Continue reading the full article.

Worked examples

Example 1 — a first encounter with Julianna Lisziewicz

Start with the simplest possible case. Write down what Julianna Lisziewicz claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In astronomy, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Julianna Lisziewicz before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Julianna Lisziewicz ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Julianna Lisziewicz

In research: Julianna Lisziewicz appears in astronomy research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Julianna Lisziewicz in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Julianna Lisziewicz is common in secondary-school and first-year university syllabi. It links to neighbouring topics Cancer researchers, Georgetown University faculty, German scientists, so understanding it makes those chapters shorter.
In everyday life: Look for Julianna Lisziewicz outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Julianna Lisziewicz in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Julianna Lisziewicz means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Julianna Lisziewicz out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Julianna Lisziewicz in simple terms?

Why does Julianna Lisziewicz matter?

Because it connects several astronomy ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Julianna Lisziewicz?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Julianna Lisziewicz.